CD79B, the second most frequently mutated gene in PCNSL, enhances B-cell receptor (BCR) signaling and NF-κB activation, thus providing survival signals to tumor cells (5, 63–65). The gene discussed is CD79B; the disease is primary central nervous system lymphoma.